Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oxford Immunotec closes $40mm Series C round

Executive Summary

Oxford Immunotec (T-cell diagnostics) raised $40mm in its Series C round led by first-time backers Clarus Ventures and Wellington Partners. Other new investor National Technology Enterprises was joined by returning shareholders Prelude Trust, Quester Capital, and Dow Chemical. The company will use the funds for the US launch of its T-SPOT.TB tuberculosis blood test. The financing is the largest in two years by a European diagnostics firm.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Cytology
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies